Department of Urology, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.
Dis Markers. 2019 Aug 27;2019:6702964. doi: 10.1155/2019/6702964. eCollection 2019.
INTRODUCTION: To investigate the correlation between preoperative De Ritis ratio (aspartate transaminase (AST)/alanine transaminase (ALT)) and postoperative outcome in patients with urothelial cell carcinoma (UC) treated with radical cystectomy. MATERIALS AND METHODS: We analyzed the clinical and pathological data of 771 patients who underwent radical cystectomy for bladder UC. Patients were divided into two groups according to the optimal value of AST/ALT ratio. The effect of the AST/ALT ratio was analyzed using the Kaplan-Meier method and Cox regression hazard models for patients' cancer-specific survival (CSS), overall survival (OS), and recurrence-free survival (RFS). In addition, propensity score matching of 1 : 1 was performed between the two groups. RESULTS: Median follow-up was 84.0 (36-275) months. Mean age was 64.8 ± 10.0 years. According to the receiver operating characteristic (ROC) analysis, the optimal threshold of the AST/ALT ratio was 1.1. In Kaplan-Meier analyses, the high AST/ALT group showed worse outcomes in CSS and OS (all < 0.001). Also, RFS ( = 0.001) in the Cox regression models of clinical and pathological parameters was used to predict CSS, OS, and AST/ALT ratio (HR 2.15, 95% CI 1.23-3.73, = 0.007) and pathological T stage (HR 4.80, 95% CI 1.19-19.28, = 0.003). To predict OS and AST/ALT ratio (HR 2.05, 95% CI 1.65-2.56, < 0.001), pathological T stage (HR 2.96, 95% CI 0.57-17.09, = 0.037) and positive lymph node (HR 1.71, 95% CI 1.50-1.91, = 0.021) were determined as independent prognostic factors. CONCLUSION: Preoperative AST/ALT ratio could be an independent prognostic factor in patients with UC treated with radical cystectomy.
简介:本研究旨在探讨根治性膀胱切除术治疗尿路上皮癌(UC)患者的术前 De Ritis 比值(天冬氨酸转氨酶(AST)/丙氨酸转氨酶(ALT))与术后结局之间的相关性。
材料与方法:我们分析了 771 例行根治性膀胱切除术的 UC 患者的临床和病理资料。根据 AST/ALT 比值的最佳值,将患者分为两组。采用 Kaplan-Meier 法和 Cox 回归风险模型分析 AST/ALT 比值对患者癌症特异性生存(CSS)、总生存(OS)和无复发生存(RFS)的影响。此外,对两组进行了 1∶1 的倾向评分匹配。
结果:中位随访时间为 84.0(36-275)个月。平均年龄为 64.8±10.0 岁。根据受试者工作特征(ROC)分析,AST/ALT 比值的最佳阈值为 1.1。Kaplan-Meier 分析显示,高 AST/ALT 组 CSS 和 OS 结局较差(均 <0.001)。此外,在临床病理参数的 Cox 回归模型中,RFS(=0.001)也可预测 CSS、OS 和 AST/ALT 比值(HR 2.15,95%CI 1.23-3.73,=0.007)和病理 T 分期(HR 4.80,95%CI 1.19-19.28,=0.003)。预测 OS 和 AST/ALT 比值(HR 2.05,95%CI 1.65-2.56,<0.001)、病理 T 分期(HR 2.96,95%CI 0.57-17.09,=0.037)和阳性淋巴结(HR 1.71,95%CI 1.50-1.91,=0.021)是独立的预后因素。
结论:术前 AST/ALT 比值可能是接受根治性膀胱切除术治疗的 UC 患者的独立预后因素。
Transl Androl Urol. 2023-5-31
Exp Cell Res. 2016-2-1